Showing results (221-230 of 282) with videos related to
Sort By:
Pageof 29
American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.Journal of Geriatric Oncology|November 30, 2024
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)Myrna Candelaria, Luis Villela, Luis F Oñate-Ocana, et al.American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.Journal of Hazardous Materials|February 12, 2022
Exposure to polystyrene microplastics impairs hippocampus-dependent learning and memory in miceChiang-Wen Lee, Lee-Fen Hsu, I-Lin Wu, et al.Haematologica|October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeMonique C Minnema, Eva Kimby, Shirley D'Sa, et al.Blood|March 3, 2018
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.British Journal of Haematology|September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control studyArtur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.Pageof 29